Landing
European Renal Association (ERA) 2025
The smouldering disease that is slowly eating away the kidneys, those people get missed: A thematic analysis of healthcare provider perspectives on the care pathway and unmet needs in C3G and primary IC-MPGN in the US and Europe
Pegcetacoplan Treatment Effect in Patients with Nephrotic Range Proteinuria: Results From the VALIANT Phase 3 Study in Patients with C3G or Primary (Idiopathic) IC-MPGN
Targeted Treatment with Pegcetacoplan for Adolescents with C3G or Primary (Idiopathic) IC-MPGN in the VALIANT Phase 3 Trial
Pegcetacoplan Demonstrates Clinically Significant Responses in C3G and Primary (Idiopathic) IC-MPGN Patients with or without Concomitant Immunosuppression in VALIANT
Proteinuria combined with other relevant markers as a clinically meaningful surrogate endpoint for measuring disease progression and treatment response in patients with C3G and primary IC-MPGN: A Delphi consensus of European experts
Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy
Targeted Treatment with Pegcetacoplan for Post-Transplant Recurrent C3G or Primary (Idiopathic) IC-MPGN in the VALIANT Phase 3 Trial
Pegcetacoplan Treatment Appears to Halt Disease Progression in C3G and Primary (Idiopathic) IC-MPGN Patients: Results from the Phase 3 VALIANT Study
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.